Completed PHASE1/PHASE2 INTERVENTIONAL NCT00519363

Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors

Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors.

Sponsor: Saint Luke's Health System

Updated 5 times since 2017 Last updated: Mar 23, 2010 Started: Sep 30, 2007 Primary completion: Oct 31, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Systemic Lupus Erythematosus and is currently completed. Saint Luke's Health System leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Saint Luke's Health System
The Center for Rheumatic Disease, Allergy, & Immunology

Data source: The Center for Rheumatic Disease, Allergy, & Immunology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kansas City, United States